CardioAI

Cardio AI is an AI-powered clinical decision platform that analyzes multimodal cardiac data — including ECG readings, echocardiography, lab values, and EHR data — to deliver:

• Diagnostic assessments synthesizing all available patient data
• Risk stratification scores identifying high-risk patients early
• Personalized treatment guidance aligned with clinical evidence
• Seamless integration into existing clinician workflows

The platform uses a multi-agent AI architecture where specialized agents collaborate to produce comprehensive, explainable recommendations — not just pattern matching on a single data source.

Most competitors offer point solutions — focusing exclusively on ECG analysis or imaging interpretation in isolation. Cardio AI takes a fundamentally different approach:

• Multi-modal integration: We analyze ECG, echo, labs, and EHR data simultaneously
• Multi-agent architecture: Specialized AI agents collaborate for comprehensive insights
• Explainability: Clinicians receive clear reasoning, not just opaque predictions
• Workflow-native: Delivered directly within existing clinical workflows
• Comprehensive output: Diagnostic + risk stratification + treatment guidance in one platform

Cardio AI targets healthcare organizations with significant cardiac patient volume and established digital infrastructure:

• Primary: Academic medical centers, large hospital systems, and cardiology departments
• Secondary: Community hospitals, women's health networks, and regional health systems
• Phase 3: National scale via payer partnerships and integrated delivery networks

Our go-to-market prioritizes organizations that can serve as reference customers and generate the real-world evidence needed to support broader commercialization and regulatory pathways.

The AI in cardiology market is growing rapidly toward the multi-billion dollar range by 2030+, driven by powerful tailwinds:

• CVD Burden: Cardiovascular disease is the #1 global cause of death, creating sustained demand for better diagnostic and predictive tools
• AI Adoption: Healthcare AI investment is accelerating as health systems seek to improve outcomes and reduce costs
• Digital Infrastructure: EHR adoption and data availability have reached levels that make AI integration practical at scale
• Reimbursement Trends: CMS and private payers increasingly recognizing AI-assisted diagnostics in coverage policies

We operate a per-member-per-month (PMPM) SaaS model with three tiers designed to match the needs and scale of different hospital customers:

Cardio AI is raising a $5M seed round to execute on the following critical milestones:

• Clinical Pilots & Beta Testing: Partner with 3–5 anchor hospitals to generate regulatory-quality performance data and real-world evidence
• FDA Clearance: Fund the regulatory submission process, external clinical advisory support, and pre-market studies required for 510(k) or De Novo clearance
• Expanded Model Capabilities: Develop real-time cardiac monitoring modules and next-generation risk stratification agents
• EHR Partnerships: Establish certified integrations with Epic, Cerner, and other major EHR platforms
• Commercialization: Build the enterprise sales infrastructure, customer success team, and marketing capabilities needed to scale post-clearance

• Working Prototype: Production-grade ECG and echocardiography models developed and validated internally
• Secure Cloud Deployment: Infrastructure in place and tested; HIPAA-compliant architecture operational
• Clinical Pilot Readiness: Operational protocols and data governance structures ready for hospital partner activation
• Market Discovery: Dozens of clinician discovery interviews conducted across cardiology, internal medicine, and hospital administration

Cardio AI has developed a structured roadmap supporting both FDA clearance (US) and CE marking (EU):

• Regulatory Pathway: Pre-Submission meeting with FDA planned to align on 510(k) vs. De Novo pathway; real-world evidence from clinical pilots will form the basis of regulatory submissions
• Clinical Validation: Phase 1 hospital pilots will collect prospective performance data; external clinical advisory board engaged to review validation protocols
• Publication Strategy: Peer-reviewed evidence base supporting broader commercialization

• Proprietary Multi-Agent Architecture: Purpose-built for multimodal cardiac data integration — a complex, non-trivial technical achievement that takes years to develop and validate
• Deep Clinical Workflow Integration: Once embedded in hospital care pathways, switching costs are substantial due to staff training, workflow redesign, and regulatory re-evaluation
• Growing Real-World Datasets: Each clinical deployment generates proprietary training data that improves model performance — a compounding data moat that widens over time
• Long-Term Hospital Partnerships: Multi-year enterprise contracts with deep EHR integrations create durable revenue streams and reference relationships
• Regulatory Clearance: FDA/CE clearance, once obtained, serves as a significant barrier to entry for new competitors

• Clinical Leadership: Board-certified cardiologist leadership ensures the platform is designed for real clinical workflows. Clinical credibility is essential for hospital sales and regulatory interactions
• AI Research & Engineering: Advanced expertise in multimodal learning, clinical NLP, and medical imaging analysis; production-grade systems development experience in regulated industries
• Enterprise Software: Proven track record building scalable, HIPAA-compliant cloud infrastructure with experience in HL7/FHIR and EHR integration
• Financial Strategy: Healthcare-focused financial expertise optimized for scaling AI platforms, including venture fundraising and enterprise healthcare procurement
• Advisory Network: Clinical, regulatory, and industry advisors providing domain expertise, hospital introductions, and regulatory guidance